Role of bile acids in atherogenesis: review

The review describes the metabolism of bile acids (BAs) in the human body, their effect on cholesterol metabolism and the development of atherosclerosis, which remains one of the most pressing problems in medicine. The problem of cholestasis is discussed, which is often found in patients with cardiovascular diseases with comorbidities, including non-alcoholic fatty liver disease and which plays a key role in the development of many complications associated with impaired BA metabolism, including hyperlipidemia, metabolic syndrome. Cholestasis treatment, which allows restoring normal cholesterol levels, are considered. Timely administration of ursodeoxycholic acid makes it possible to prevent atherosclerosis (primary prevention of atherosclerosis), because with normal bile metabolism, the levels of proatherogenic lipids are normalized and the production of inflammatory mediators, high levels of which contribute to atherogenesis, decreases. In this review, the author presents the important role of bile metabolism in the primary and secondary prevention of atherosclerosis and the possibility of solving this issue by prescribing ursodeoxycholic acid and changing lifestyle.

1. Fan J, Watanabe T. Atherosclerosis: Known and unknown. Pathol Int. 2022;72(3):151-60. doi:10.1111/pin.13202.

2. Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid me­tabolism. Clinical recommendations 2023. Russian Jour­nal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.

3. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014.

4. Pirillo A, Casula M, Catapano AL. European guidelines for the treatment of dyslipidaemias: New concepts and future chal­lenges. Pharmacol Res. 2023:196:106936. doi:10.1016/j.phrs.2023.106936.

5. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012;110(6):823-5. doi:10.1016/j.amjcard.2012.04.062.

6. Ershova AI, Al Rashi DO, Ivanova AA, et al. Secondary hyper­lipidemia: etiology and pathogenesis. Russian Journal of Car­diology. 2019;(5):74-81. (In Russ.) doi:10.15829/1560-4071-2019-5-74-81.

7. Ivashkin VT, Shirokova YeN, Mayevskaya MV, et al. Clinical guidelines of the Russian gastroenterological association and the Russian society on study of the liver on diagnostics and treatment of cholestasis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(2):41-57. (In Russ.)

8. Alveirinho M, Freitas P, Faleiro ML. Role of gut microbiota in me­tabolic syndrome: a review of recent evidence. Porto Biomed J. 2020;5(6):e105. doi:10.1097/j.pbj.0000000000000105.

9. Volovnikova VA, Kotrova AD, Ivanova KA, et al. Role of intestinal mi­crobiota in the development of obesity. Juvenis Scientia. 2019;6:4-10. (In Russ.) doi:10.32415/jscientia.2019.06.01.

10. Yevsyutina YuV, Ivashkin VT. Metabolism of bile acids, liver di­seases and microbiome. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(2):4-10. (In Russ.) doi:10.22416/1382-4376-2018-28-2-4-10.

11. Porez G, Prawitt J, Gross B, et al. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53:1723-37. doi:10.1194/jlr.R024794.

12. Arias IM, Alter HJ, Boyer JL, et al. Thorgeirsson, Allan W. Wolkoff. The Liver: Biology and Pathobiology. John Wiley & Sons, 2020. Total pages: 1152. ISBN: 1119436834, 9781119436836.

13. Hylemon PB, Zhou H, Pandak WM, et al. Bile acids as regulatory mo­lecules. J Lipid Res. 2009;50:1509-20. doi:10.1194/jlr.R900007-JLR200.

14. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167-77. doi:10.1016/j.cmet.2009.08.001.

15. Guan B, Tong J, Hao H, et al. Bile acid coordinates micro­biota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharm Sin B. 2022;12(5):2129-49. doi:10.1016/j.apsb.2021.12.011.

16. Hu YB, Liu XY, Zhan W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis. Drug Des Devel Ther. 2018;12: 2213-21. doi:10.2147/DDDT.S170518.

17. Yoo JY, Sniffen S, McGill Percy, et al. Gut Dysbiosis and Immu­ne System in Atherosclerotic Cardiovascular Disease (ACVD). Micro­organisms. 2022;10:108. doi:10.3390/microorganisms10010108.

18. Tyuryumin YaL, Shanturov VA, Tyuryumina EE. Physiology of cholesterol metabolism (The review). Acta Biomedica Scientifica. 2012;2(1):153-8. (In Russ.)

19. Butorova LI. Cholesterosis of the gallbladder: pathogenesis, clinic, diagnosis, principles of conservative therapy: manual for doctors. Moscow: Forte Print, 2012. 52 p. (In Russ.) ISBN: 978-5-905757-04-4.

20. Vakhrushev YaM, Gorbunov AYu, Tronina DV, et al. Cholelithiasis as a possible manifestation of systemic digestive diseases. Therapeutic Archive. 2015;87(2):54-8. (In Russ.) doi:10.17116/terarkh201587254-58.

21. Polunina TE. Cholestasis: algorithms for diagnosis and treat­ment. Academy of medicine and sports. 2021;2(4):28-36. (In Russ.) doi:10.15829/2712-7567-2021-43.

22. Recommendations of experts of the All-Russian Scientific Society of Cardiologists on the diagnosis and treatment of metabolic syn­drome. Second revision. ed. by I. Е. Chazova. Practical Medi­cine. 2010;5(44):81-101. (In Russ.)

23. Baratta F, Pastori D, Angelico F et all. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. Clin Gastroenterol Hepatol. 2020;18(10):2324-31.e4. doi:10.1016/j.cgh.2019.12.026.

24. Galeeva ZM, Gimaletdinova IA, Amirov NB. Nonalcoholic fatty liver disease and atherogenic dyslipidemia. What problems arise in cardiologist? Bulletin of Modern Clinical Medicine. 2014;7(1):55-9. (In Russ.)

25. Wu Sh, Wu F, Ding Y, et al. Association of non-alcoholic fatty liver di­sea­se with major adverse cardiovascular events: A systematic re­view and meta-analysis. Sci Rep. 2016;16:6:33386. doi:10.1038/srep33386.

26. Lepage P, Leclerc MC, Joossens M, et al. A metagenomic insight into our gut’s microbiome. Gut. 2013;62:146-58. doi:10.1136/gutjnl-2011-301805.

27. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.

28. Chen D, Yang Z, Chen X, et al. Effect of lactobacillus rhamnosus hsryfm 1301 on the gut microbiota and lipid metabolism in rats fed a high-fat diet. J Microbiol Biotechnol. 2015;25(5):687-95. doi:10.4014/jmb.1409.09085.

29. Parasar B, Zhou H, Xiao X, et al. Chemoproteomic Profiling of Gut Microbiota-Associated Bile Salt Hydrolase Activity. 2019;5(5): 867-73. doi:10.1021/acscentsci.9b00147.

30. Lye H-S, Kato T, Low W-Y, et al. Lactobacillus fermentum FTDC 8312 com­bats hypercholesterolemia via alteration of gut microbio­ta. Jour­nal of Biotechnology. 2017;262:75-83. doi:10.1016/j.jbiotec.2017.09.007.

31. Öner Ö, Aslim B, Aydaş SB. Mechanisms of cholesterol-lowering effects of lactobacilli and bifidobacteria strains as potential pro­biotics with their bsh gene analysis. 2014;24(1):12-8. doi:10.1159/000354316.

32. Costabile A, Buttarazzi I, Kolida S, et al. An in vivo assessment of the cholesterollowering efficacy of lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. PLoS One. 2017;12(12):e0187964. doi:10.1371/journal.pone.0187964.

33. Baars A, Oosting A, Lohuis M, et al. Sex differences in lipid metabolism are affected by presence of the gut microbiota. Sci Rep. 2018;8(1):13426. doi:10.1038/s41598-018-31695-w.

34. Heinken A, Ravcheev DA, Baldini F, et al. Systematic assessment of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in inflammatory bowel disease. Microbiome. 2019;7(1):75. doi:10.1186/s40168-019-0689-3.

35. Sayin SI, Wahlström A, Felin J, et al. Gutmicrobiota regulates bile acid metabolism by reducing the levels of taurobetamuricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2):22535. doi:10.1016/j.cmet.2013.01.003.

36. Khavkin AI, Volynets GV, Nikitin AV. Interrelation of intestinal mic­robiome and metabolism of bile acids. Voprosy prakticheskaya pediatriya. 2020;15(1):53-60. (In Russ.) doi:10.20953/1817-7646-2020-1-53-60.

37. Gargari G, Deon V, Taverniti V, et al. Evidence of dysbiosis in the in­testinal microbial ecosystem of children and adolescents with primary hyperlipidemia and the potential role of regular hazelnut intake. FEMS. Microbiol Ecol. 2018;94:fiy045. doi:10.1093/femsec/fiy045.

38. Moreno-Indias I, Sánchez-Alcoholado L, Pérez-Martínez P, et al. Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. Food Funct. 2016;7:1775-87. doi:10.1039/c5fo00886g.

39. Koh A, De Vadder F, Kovatcheva-Datchary P, et al. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016;165:1332-45. doi:10.1016/j.cell.2016.05.041.

40. Dabke K, Hendrick G, Devkota S. The gut microbiome and meta­bolic syndrome. J Clin Investig. 2019;129:4050-7. doi:10.1172/JCI129194.

41. Kaska L, Sledzinski T, Chomiczewska A, et al. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World J Gastroenterol. 2016;22:8698-719. doi:10.3748/wjg.v22.i39.8698.

42. Cariou B, van Harmelen K, Duran-Sandoval D, et al. The farnesoid X re­ceptor modulates adiposity and peripheral insulin sensitivity in mi­ce. J Biol Chem. 2006;281:11039-49. doi:10.1074/jbc.M510258200.

43. Langhi C, Le May C, Kourimate S, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS. Lett. 2008;582:949-55. doi:10.1016/j.febslet.2008.02.038.

44. Baranovsky AYu, Raikhelson KL, Semenov NV, et al. Principles of treatment of cholestatic liver diseases. The attending physician. 2012;(07):43-50. (In Russ.)

45. Hilscher MB, Kamath PS, Eaton JE. Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. 2020 Mayo Foun­dation for Medical Education and Research. Mayo Clin Proc. 2020;95(10):2263-79. doi:10.1016/j.mayocp.2020.01.015.

46. Drapkina OM, Bueverova EL. Ursodeoxycholic acid: therapeutic niche in the internist's practice. Therapeutic Archive. 2015; 87(4):84-90. (In Russ.) doi:10.17116/terarkh201587484-90.

47. Guarino MPL, Cocca S, Altomare A, et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol. 2013;19(31):5029-34. doi:10.3748/wjg.v19.i31.5029.

48. Bode N, Grebe A, Kerksiek Ф, et al. Ursodeoxycholic acid impairs atherogenesis and promotes plaque regression by cholesterol crystal dissolution in mice. Biochem Biophys Res Commun. 2016;478(1):356-62. doi:10.1016/j.bbrc.2016.07.047.

49. Nadinskaia М, Maevskaya М, Ivashkin V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(10):959-75. doi:10.3748/wjg.v27.i10.959.

50. Huang K, Liu C, Peng M, et al. Glycoursodeoxycholic Acid Ameliorates Atherosclerosis and Alters Gut Microbiota in Apolipoprotein E-Deficient Mice. J Am Heart Assoc. 2021;10(7): e019820. doi:10.1161/JAHA.120.019820.

51. Simental-Mendía LE, Simental-Mendía M, Sánchez-García A, et al. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Lipids Health Dis. 2019;18(1):88. doi:10.1186/s12944-019-1041-4.

52. Cabezas Gelabert R. Efecto del acido ursodesoxicolico combinado con estatinas para el tratamiento de la hipercolesterolemia: ensayo clinico prospectivo. Rev Clin Esp. 2004; 204(12):632-5. doi:10.1016/s0014-2565(04)71566-0.

53. Martsevich SYu, Kutishenko NP, Drozdova Lyu, et al. Study of the effect of ursodeoxycholic acid on the efficacy and safety of statin therapy in patients with liver, gallbladder and/or biliary tract diseases (RACURS study). Rational Pharmacotherapy in Cardiology. 2014;10(2):147-52. (In Russ.) doi:10.20996/1819-6446-2014-10-2-147-152.